|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Mark Joseph Enyedy||Pres, CEO & Director||1,24M||N/D||1964|
|Ms. Susan Altschuller Ph.D.||Sr. VP & CFO||537,53k||N/D||1983|
|Dr. Anna Berkenblit M.D., MM.Sc||Sr. VP & Chief Medical Officer||647,28k||N/D||1970|
|Ms. Stacy A. Coen||Sr. VP & Chief Bus. Officer||547,66k||N/D||1971|
|Ms. Kristen Harrington-Smith||Sr. VP & Chief Commercial Officer||562,52k||N/D||1973|
|Ms. Renee Lentini||VP of Fin. & Principal Accounting Officer||N/D||N/D||1978|
|Ms. Courtney O'Konek||Sr. Director of Corp. Communications & Investor Relations||N/D||N/D||N/D|
|Mr. Joseph J. Kenny||VP, Acting Gen. Counsel, Intellectual Property & Sec.||N/D||N/D||N/D|
|Ms. Audrey Bergan||Sr. VP & Chief HR Officer||N/D||N/D||N/D|
|Dr. Theresa G. Wingrove||Sr. VP of Regulatory Affairs & Quality||N/D||N/D||1958|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
L'ISS Governance QualityScore di ImmunoGen, Inc. al 31 luglio 2022 è 5. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 5; retribuzione: 6.